Oncodesign Precision Medicine Announces the Initiation of Phase I of its RIPK2 Inhibitor ODS-101, a
First-in-Man study of ODS-101 in healthy volunteersDIJON, France--(BUSINESS WIRE)--Regulatory News:Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM) (Paris:ALOPM), a clinical stage biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cance...
Source: pharmiweb.com